Trial Profile
Open-Labeled, Randomized Multi-Center Phase II Study Evaluating the Efficacy and Safety of Paclitaxel/Carboplatin With and Without Cetuximab as First-Line Treatment of Adeno- and Undifferentiated Carcinoma of Unknown Primary (CUP).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Bone metastases; Cancer; Cancer metastases; Carcinoma; Liver metastases
- Focus Therapeutic Use
- Acronyms PACET-CUP
- 25 Nov 2020 Primary endpoint (The rate of progression free survival at 8 months after randomization, defined as the proportion of patients alive with stable disease, partial or complete response, according to RECIST is the primary endpoint for the final analysis.) has not been met, according to results published in the British Journal of Cancer
- 25 Nov 2020 Results published in the British Journal of Cancer
- 14 Feb 2020 Status changed from recruiting to completed.